Antria Inc — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$4,058	2
2024	Research	$69,451	1
2023	Research	$900	11
2022	Research	$1,250	2
2021	Research	$98,336	9
2020	Research	$49,214	13
2019	Research	$134,996	24

Breakdown

Who paid Research payments · program years 2019–2025

Regeneron Pharmaceuticals, Inc. $224,239 36 payments
Novartis Pharmaceuticals Corporation $69,509 2 payments
Endo Pharmaceuticals Inc. $42,625 6 payments
Pfizer Inc. $15,070 4 payments
IBSA Institut Biochimique SA $4,000 1 payment
AstraZeneca Pharmaceuticals LP $2,062 3 payments
GRT US Holding, Inc. $700 10 payments

Studies the money was for Research payments · program years 2019–2025

Phase 3 Randomized, Double-Blind, Multi-Dose, Placebo and Nsaid Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Pain Due to Osteoarthritis of the Knee Or Hip $219,889 34 payments
A randomized, parallel-group, 24 week, double-blind, placebo-controlled, multicenter Phase 3 study to assess the efficacy and safety of secukinumab compared to placebo in adult patients with active rotator cuff tendinopathy $69,509 2 payments
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of En3835 for the Treatment of Adhesive Capsulitis of the Shoulder $38,750 4 payments
A Phase 3B Randomized Doubleblind Doubledummy Active Controlled Multicenter Study Assessing the Efficacy and Safety of Abrocitinib Compared With Dupilumab in Adult Participants on Background Topical Therapy With Moderate to Severe Atopic Dermatitis $10,070 3 payments
An Openlabel Extension Study to Assess the Longterm Safety and Efficacy of Pf04965842 in Adult Patients With Moderatetosevere Atopic Dermatitis $5,000 1 payment
Study to Evaluate Arthroplasty Specimens in the Phase 3 Fasinumab Program for Osteoarthritis of the Knee and Hip $4,350 2 payments
18US-FHp04/A multi-center, prospective, open-label, controlled study of the pharmacokinetics and safety of the LicartTM topical system in pediatric and adult participants with minor soft tissue injuries $4,000 1 payment
Observational, Investigator blinded, Long-Term Post-injection Study to Evaluate the Safety and Durability (Efficacy) of Response to EN3835 compared to placebo in the Treatment of Adhesive Capsulitis of the shoulder (Frozen Shoulder) $3,875 2 payments
Dapagliflozin Effect on Cardiovascular Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes $2,062 3 payments
A Randomized Doubleblind Placebocontrolled Phase III Trial to Evaluate the Efficacy and Safety of A Single Intraarticular Injection of Rtxgrt7039 in Adult Subjects With Pain Associated With Osteoarthritis of the Knee $700 10 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.